AbCellera Investor Presentation Deck

FULL YEAR 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 COVID-19 ANTIBODY PROGRAM. Similar revenue structure to typical program realized on a compressed timeline. Months since program start Stage of program development research fees <$5 million 3m discovery & preclinical approval & commercial milestones $14 million clinical milestones $8 million 6m 9m clinical development 12m 15m commercial sales royalties in aggregate of $526 million (to Dec 31, 2021), over 95% of total program revenue 18m 21m 24m

View entire presentation